Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.
Launched by CUMA BULENT GUL · Mar 10, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
This study explores the association between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients. Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in chronic kidney disease (CKD) patients undergoing hemodialysis. However, a significant proportion of patients exhibit hyporesponsiveness to ESAs, leading to suboptimal anemia management. SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase, regulates hypoxia and iron metabolism by modulating the activity of hypoxia-inducible factor 1α (HIF-1α). Lower SIRT1 levels ma...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥18 years
- • Receiving hemodialysis
- • Availability of laboratory data to calculate ERI
- Exclusion Criteria:
- • Autosomal polycystic kidney disease
- • Malignancies
- • Infectious diseases
- • Chronic rheumatological disorders
- • Vitamin B12 or folic acid deficiency
- • CRP levels ≥ 5 mg/L
- • PTH levels ≥ 300 pg/dL
- • Inadequate hemodialysis (Kt/Vurea \< 1.2)
About Cuma Bulent Gul
Cuma Bulent Gul is a distinguished clinical trial sponsor known for his commitment to advancing medical research and enhancing patient care. With extensive experience in the pharmaceutical and biotechnology sectors, he focuses on facilitating innovative trials that address unmet medical needs. Under his leadership, the organization emphasizes rigorous scientific methodologies, ethical standards, and collaboration with healthcare professionals to ensure the successful development of new therapies. Cuma Bulent Gul is dedicated to fostering a patient-centered approach, driving progress in healthcare through meticulous research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bursa, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported